FDA plans in 2017 to ask an advisory committee whether a risk of serious bleeding linked to use of OTC antacid/aspirin products should spur further agency action than a label warning currently required for the products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?